<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05021315</url>
  </required_header>
  <id_info>
    <org_study_id>82019</org_study_id>
    <nct_id>NCT05021315</nct_id>
  </id_info>
  <brief_title>Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection</brief_title>
  <official_title>Effect of Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of work to assess the effectiveness of preoperative vaginal cleansing with povidone&#xD;
      iodine on reduction of post caesarean section wound infection&#xD;
&#xD;
      Research questions:&#xD;
&#xD;
      Does vaginal cleaning using povidone iodine before cesarean section has effect on reduction&#xD;
      of postoperative wound infection??&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 15, 2019</start_date>
  <completion_date type="Actual">March 15, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative wound complication</measure>
    <time_frame>1 week</time_frame>
    <description>Any sign of infection as redness, hotness and tenderness as well as pyrexia occurance in wound postoperative</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cesarean Section Complications</condition>
  <condition>Vaginal Infection</condition>
  <condition>Postoperative Infection</condition>
  <arm_group>
    <arm_group_label>Iodine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 women who received preoperative vaginal cleansing with 10% povidone iodine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 women who did not receive preoperative vaginal cleansing even with tap water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10% povidone iodine</intervention_name>
    <description>50 women who received preoperative vaginal cleansing with 10% povidone iodine.</description>
    <arm_group_label>Iodine group</arm_group_label>
    <other_name>Betadine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Pregnant women who are 37 weeks gestation or more scheduled for elective caesarean&#xD;
             section or those in labor with limited number of vaginal examination less than 5 times&#xD;
             preoperatively.&#xD;
&#xD;
             2. Pregnant women who are 37 weeks gestation or more with rupture of membranes but&#xD;
             duration less than 24 hours&#xD;
&#xD;
             3.Women consenting to be included in the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Abnormally invasive placenta and placenta previa.&#xD;
&#xD;
          2. Intra-partum fever.&#xD;
&#xD;
          3. Prolonged rupture of membranes more than 24 hours&#xD;
&#xD;
          4. History of exposure to radiation treatment for cancer.&#xD;
&#xD;
          5. History of Gynecological infections (PID).&#xD;
&#xD;
          6. History of abdominal infections eg: peritonitis.&#xD;
&#xD;
          7. Debilitating diseases like Diabetes mellitus, Thyroid disorders, Cushing disease,&#xD;
             abdominal malignancy.&#xD;
&#xD;
          8. Obesity defined as pregnant BMI &gt;30 kg/m2.&#xD;
&#xD;
          9. History of wound infection or burst abdomen.&#xD;
&#xD;
         10. History suggestive of massive bleeding during previous cesarean section.&#xD;
&#xD;
         11. allergy to iodine containing solutions&#xD;
&#xD;
         12. Pregnant women with severe anemia defined as Hb &lt;7 g/dl.&#xD;
&#xD;
         13. Cases with intra-abdominal drain deployment are discarded.&#xD;
&#xD;
         14. Obstructed labor with numerous vaginal examinations.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mostafa A Sleem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ethical and scientific committee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>faculty of medicine - Cairo university</name>
      <address>
        <city>Cairo</city>
        <state>Kasr El Ainy</state>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>ahmed nagy shaker ramadan</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

